Alnylam gets FDA nod for first-ever RNAi drug

The U.S. FDA has approved Alnylam Pharmaceuticals’ Onpattro, making it the first medicine specifically cleared to treat a rare and deadly disease called hereditary transthyretin amyloidosis.Original Article